Nebenwirkungen · Hyrimoz
Hyrimoz 20 mg solution for injection in pre-filled syringe Hyrimoz 40 mg solution for injection in pre-filled syringe Hyrimoz 40 mg solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 22
HOS-137741 · Präparat HOS-098091
Not known Weight increased2) Injury, poisoning and Common Impaired healing procedural complications * further information is found elsewhere in sections 4.3, 4.4 and 4.8 ** including open label extension studies 1) including spontaneous reporting data 2) The mean weight change from baseline for adalimumab ranged from 0.3 kg to 1.0 kg across adult indications compared to (minus) -0.4 kg to 0.4 kg for placebo over a treatment period of 4- 6 months. Weight increase of 5-6 kg has also been observed in long-term extension studies with mean exposures of approximately 1-2 years without control group, particularly in patients with Crohn’s disease and ulcerative colitis. The mechanism behind this effect is unclear but could be associated with the anti-inflammatory effect of adalimumab.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-13T10:00:00Z · SHA-256 bb2e47f3048e41368975094658eb6e77cdd9bd77fdb14fd3af35a8737fa4ae2c · Passage c9a72197b0c7eded41f149c7a089ec875622d1cec3a55ecca7ab584f20176974 · Zeichen 13814–14680 im Abschnitt